Are intravitreal anti-VEGF antibodies safe?
Tezel
Tongalp H
TH
Kaplan
Henry J
HJ
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D052157:Aptamers, Nucleotide / Q000008:administration & dosage / Q000009:adverse effects*; D005122:Exudates and Transudates; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib